Xiangxue Pharmaceutical announced that Guangzhou Pharmaceutical Capital Co., Ltd. has been selected as the winning investor in the company's restructuring. The selection result came from the restructuring investor selection review meeting held on June 30, 2026, but as of now, the company has not yet signed a pre-restructuring investment agreement with the selected party, and specific terms have not been determined, so there is uncertainty about whether a final agreement can be reached. Since launching pre-restructuring in April 2025, the company has extended the pre-restructuring period four times, with the current deadline extended to July 11, 2026. The announcement also cautioned that this pre-restructuring does not mean the court will ultimately accept the restructuring application. If the court formally accepts it, the company's shares will be subject to delisting risk warning. If the restructuring fails and bankruptcy is declared, the shares will face the risk of termination of listing.
Xiangxue PharmaceuticalInvestor selected for restructuring but no signed agreement; uncertainty and delisting risk remain.